Reader comment on: EpiPen-Maker Mylan's Lobbying
Submitted by Joseph N. Brady (United States), Aug 30, 2016 12:24
Dear Mr.Stoll, Your article in today's Post re the EpiPen prompts me to tell you about a Mylan drug that I am presently taking to control "A-FIB" called "MULTAQ". At the beginning of the year I was paying approx. $400 for a roughly month and a half supply through my FDNY drug plan with "Express Scripts". The last payment I made was over one thousand dollars. The math tells me I'm paying approx. nine to ten thousand dollars a year. I have called Mylan to see if I would be eligble for some relief and was put on a merry-go -round of negative answers. This thing is breaking me. It's easy therefore to conclude that Mylan's entire portfolio of drugs should be scrutinized, not just the EpiPen. Thanks for the chance to vent.
Note: Comments are moderated by the editor and are subject to editing.
Comment on this item